Drugs / 1,3 beta-Glucans
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05465798 | Jun 2023 → Oct 2024 | COVID-19 | Wohlstand Pharmaceutical | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 1,3 beta-Glucans | “Patients allocated to this arm will receive MC 3x3, an oral supplement containing 25mg of 1,3 beta-Glucans of fungal origin (Trichoderma sp.) daily for up to three consecutive days.” NCT05465798 ↗ |
| Modality | Other / unclassified | “Beta-glucans comprise a heterogeneous group of natural polysaccharides” NCT05465798 ↗ |
| Route | Oral | “an oral supplement containing 25mg of 1,3 beta-Glucans” NCT05465798 ↗ |